Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by juansitoon Jun 24, 2018 5:04pm
98 Views
Post# 28221174

meeting agenda

meeting agendahttps://www.investorx.ca/PDF/1806051504200448/(ico-therapeutics-inc)(management-information-circular-english)(06-05-2018)?Mobile=False

I dont expect any spectacular outcome here...
mostly du tu pass financials and re elect directors 
next NR for end of Q3 or a little later (final data on Ico009/19)

for IMNP I think all the rally is du to Ico009/19
market didnt take in account Ico008

the sp move was after ICO 009/19 NR (including the dd some potential partnerts are doing)

I got out and back in as dr descrive as sharp money...any way im down more than 10$K from my last possition (average 17 cents) and intenting to stay calm. I think we gonna see more than 30 cents before year ends.

i short term anything can happens...a lot of HFT and day traders making noise...

but core up trend should resume (I think is more a week time frame that we should look)

I really like the 5 years chart...imo going back to promise company land around 30=50 cents price share fare value...

just my 13,5 cents...

GLTA
eom
<< Previous
Bullboard Posts
Next >>